A dispute worth hundreds of millions of dollars is, before anything else, a balance-sheet problem. Expert evidence, disclosure, counsel fees, court time and the risk of an adverse costs order all accumulate on a timetable that rarely matches a claimant’s ability to keep paying for them. Third-party litigation funding – usually shortened to TPLF – exists to bridge that gap. An outside investor covers some or all of the cost of a claim in exchange for a share of whatever the claim eventually recovers.
The feature that defines the whole product is that the money is generally non-recourse: if the claim fails, the funded party typically owes nothing and the investor absorbs the loss. That single term is what separates litigation finance from an ordinary loan, and it shapes almost every other part of the arrangement – who can invest, how returns are structured, and why regulators treat it as a category of its own.
What “third-party” actually means
The funder is neither a party to the dispute nor the claimant’s lawyer. In the commercial market the counterparty is commonly a company or a law firm, and the sums involved are substantial: the U.S. Government Accountability Office describes commercial arrangements as “typically in the millions of dollars.” Consumer funding is a different product altogether – usually a few thousand dollars advanced to an individual against a personal injury claim – and it is regulated separately, and more tightly, in many U.S. states.
It is worth being precise about a term that gets used loosely. Litigation funding is not the same as a contingency fee, where the claimant’s own lawyer takes the case in exchange for a share of the recovery, and it is not the same as legal expenses insurance. All three spread risk, but the funder’s money comes from outside the lawyer-client relationship, and the funder is paid by contract rather than by a fee agreement with the client.
Where the capital comes from
Funders are mostly intermediaries. The GAO found that litigation funders “obtain investment capital from a variety of investors, such as endowments and pensions,” with sovereign wealth funds also participating in the commercial market. Behind a single funding commitment, then, there is often a fund with limited partners, a defined investment horizon and a mandate that constrains which claims it can take on.
That detail matters more than it first appears. Because the ultimate capital is pooled and return-seeking, funders tend to behave less like patrons and more like specialist asset managers: they diversify across matters, size positions to the portfolio, and recycle capital as cases resolve. A claimant is not simply dealing with a deep pocket; it is dealing with an investor subject to its own fundraising and liquidity cycle.
The shapes a funding deal usually takes
The market broadly divides into a few recognisable structures, and the choice between them depends on the size, duration and risk profile of the underlying matters.
| Structure | How it works | Typical scale |
|---|---|---|
| Single-case funding | The funder finances one claim, and repayment comes only from that claim’s recovery. | Single-matter deals averaged about $4.5 million in 2025. |
| Portfolio funding | The funder finances a group of cases, often across a law firm’s docket, spreading risk between matters. | Portfolio transactions averaged about $19.6 million in 2025 and made up roughly 64% of new commitments. |
| Facility or tranche arrangements | Capital is committed up front and drawn down in stages as a case passes agreed milestones. | Varies with case size and procedural stage. |
| Claim monetisation | The claimant borrows against, or sells, an entitlement to future proceeds rather than funding present legal costs. | About 17% of new capital commitments in 2025. |
Figures: Westfleet Advisors, The Westfleet Insider: 2025 Litigation Finance Report, covering U.S. commercial litigation finance.
The structural trend over the past several years has been toward portfolios rather than one-off bets, because aggregation lets a funder accept more cases at a lower blended cost of risk. Claim monetisation – taking cash now against a recovery that has not yet landed – has also become a larger share of the market, particularly for corporate claimants that would rather not wait years to realise value from a strong claim.
How the funder is paid
Compensation is set out in the funding agreement and generally takes one of three forms: a multiple of the capital invested, a percentage of any recovery, or a combination of the two. The amount crystallises only on a successful resolution. If the claim fails, the funder’s return is typically nothing.
Where a percentage is used, the agreement usually specifies an order of payment – a waterfall – determining what comes out of a settlement or judgment first. It may also define milestones, termination rights and cross-collateralisation, under which recoveries from one matter in a portfolio can offset losses on another. Reporting of individual deal terms is sparse, which is one reason the GAO identified a “gap in the availability of market data,” including funders’ rates of return.
Because each deal is bespoke, outcomes across the market vary widely, and a funding commitment is not a guaranteed return for anyone involved. As further industry reporting and the annual survey data both illustrate, individual funding arrangements can unfold in very different ways depending on how the underlying claim resolves.
Underwriting: the part that looks like venture capital
Before committing capital, a funder evaluates a claim much as an investor evaluates a business: merits, likely damages, recoverability of any judgment, the defendant’s ability to pay, and – critically – timing. Legal spend can run for years before a return is realised, so a claim can be meritorious and still be unattractive if the money is tied up too long or the defendant’s solvency is doubtful.
This screening function is frequently described as one of the more misunderstood parts of the model. A funder earns nothing if the claim loses, so the economics push toward claims with a defensible legal theory and identifiable recovery, not merely large headline damages. The corollary is that most funding applications are declined – the sector is selective by design, not a universal payer of legal bills.
Regulation is a patchwork, not a single rulebook
How litigation finance is governed depends heavily on where the case is heard, and there is no harmonised global framework.
- United States. The GAO reported that the industry “is not specifically regulated under U.S. federal law,” although some states regulate consumer funding by, for example, capping fees. There is no nationwide requirement to disclose funding agreements to courts, though individual judges and districts have ordered disclosure in specific cases.
- England and Wales. A 2023 Supreme Court ruling, R (PACCAR) v Competition Appeal Tribunal, held that certain funding agreements counted as damages-based agreements and were therefore unenforceable, creating uncertainty across the market. The Civil Justice Council’s final report on litigation funding, published in June 2025, made 58 recommendations, led by legislation to reverse PACCAR and a “light-touch” statutory regime that would reject mandatory caps on funder returns.
- European Union. The European Parliament recommended a responsible-funding framework in 2022, but the European Commission concluded in November 2025 that it would not propose EU-level legislation for now, prioritising monitoring of the Representative Actions Directive instead. National markets remain uneven: Germany has no general TPLF statute but has capped funders’ share of gains in certain redress actions.
Disclosure is the most active issue across jurisdictions. Courts and policymakers have broadly converged on the view that transparency about the existence of funding – as distinct from its commercial terms – is a proportionate way to manage conflicts and procedural integrity, while leaving the funding market itself largely intact.
What the market data actually shows
Headline numbers for the size of the industry vary widely, and much of the confusion comes from mixing measures that are not comparable. Assets under management, capital committed to new deals in a single year, and the total value of claims funded are three different figures, and public reporting is thin enough that they are often quoted interchangeably.
| Metric | Figure | Source and period |
|---|---|---|
| U.S. commercial funding commitments | About $2.8 billion across 346 new deals | Westfleet Advisors, 2025 report |
| Active U.S. commercial funders | 39 | Westfleet Advisors, 2025 report |
| Change in new commitments, 2025 vs 2024 | Up about 23% | Westfleet Advisors, 2025 report |
| Change in new commitments, 2024 vs 2023 | Down 16% | Westfleet Advisors, 2024 report |
| Deals fully or partly insured | About 21% of new commitments | Westfleet Advisors, 2025 report |
Taken together, the annual Westfleet data tell a more modest story than the “explosive growth” framing sometimes used in public debate. The market contracted through 2023 and 2024 as capital became harder to raise, then rebounded by roughly a fifth in 2025 without returning to earlier peaks. Patent matters have remained the single largest category of funded claims, and co-investment – two or more funders sharing a deal – has become more common as a way to manage exposure on larger matters.
The argument for funding – and the argument against it
Supporters of the model focus on access to capital. A claimant with a strong case but limited cash, or a company that would rather not tie up working capital for years, can pursue a remedy it might otherwise abandon. Funders point out that because they are repaid only on success, they have an incentive to screen out weak claims, and that the risk they carry is genuinely transferred away from the claimant.
Critics raise different concerns, and they are worth stating plainly rather than dismissing. One is transparency: the GAO noted limited public data on an industry that operates largely in private, and disclosure rules vary by jurisdiction. Another is the practical effect of a third party’s participation on settlement dynamics, since a funder’s return expectations may enter negotiations that would otherwise involve only two parties. A third is allocation of control – how much say a funder has over case strategy – which several jurisdictions now address directly in their proposed frameworks.
Notably, mainstream reform proposals have generally not treated funding as illegitimate. The Civil Justice Council’s recommendations, for instance, endorse funding’s role in access to justice and propose regulation rather than restriction, explicitly rejecting return caps as too blunt for the varied risk profiles of funded claims. That balance – accepting the product while tightening its governance – is the emerging consensus in several major markets.
What to watch next
The direction of travel over the next few years depends less on whether litigation finance exists than on how it is disclosed and supervised. Three things are likely to matter most: whether England and Wales actually legislate to restore the enforceability of funding agreements after PACCAR; whether U.S. courts and states continue adding disclosure requirements piecemeal; and whether Europe’s decision to monitor rather than legislate holds as the Representative Actions Directive is implemented across member states.
For anyone trying to understand a large case, the practical takeaway is that the funding arrangement is now part of the litigation itself. The merits still decide who wins; the structure of the capital behind the claim helps decide which claims are brought, how long they run, and what a resolution has to look like before everyone at the table can agree to it.
